Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's lead asset is KVA12.1, a VISTA blocking immunotherapy. Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's lead asset is KVA12.1, a VISTA blocking immunotherapy.
Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in...
SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address...
TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in...
Kineta will be trading under the symbol “KANT” on OTC Pink Kineta will continue to pursue strategic alternatives as previously announced TuHURA Biosciences has an exclusivity right and a right...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.5746 | 0.5746 | 0.5746 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.5746 | 0.5746 | 0.5746 | 0 | 0 | CS |
| 12 | -0.0664 | -10.3588143526 | 0.641 | 0.889 | 0.5599 | 26421 | 0.68209385 | CS |
| 26 | 0.1046 | 22.2553191489 | 0.47 | 0.889 | 0.42 | 376200 | 0.6312318 | CS |
| 52 | -2.7254 | -82.5878787879 | 3.3 | 4.77 | 0.3339 | 293254 | 0.65695842 | CS |
| 156 | -8.3054 | -93.5292792793 | 8.88 | 9 | 0.3339 | 165137 | 0.93033596 | CS |
| 260 | -8.3054 | -93.5292792793 | 8.88 | 9 | 0.3339 | 165137 | 0.93033596 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
